|
[1]
|
G. Petrikkos, A. Skiada, O. Lortholary, E. Roilides, T. J. Walsh and D. P. Kontoyiannis, “Epidemiology and Clinical Manifestations of Mucormycosis,” Clinical Infectious Diseases, Vol. 54, No. S1, 2012, pp. S23-S34.
http://dx.doi.org/10.1093/cid/cir866
|
|
[2]
|
M. N. Gamaletsou, N. V. Sipsas, E. Roilides and T. J. Walsh, “Rhino-Orbital-Cerebral Mucormycosis,” Current Infectious Disease Reports, Vol. 14, No. 4, 2012, pp. 423434.
http://dx.doi.org/10.1007/s11908-012-0272-6
|
|
[3]
|
J. G. Cortez, A. Speidel, C. Peixoto, E. Selicka, C. Valente, P. Figueiredo and A. Vieira, “Mind the Gap: Management of an Emergent and Threatening Invasive Fungal Infection—A Case Report of Rhino-Orbital-Cerebral and Pulmonary Mucormycosis,” Medical Mycology Case Reports, Vol. 2, 2013, pp. 79-84.
http://dx.doi.org/10.1016/j.mmcr.2013.02.008
|
|
[4]
|
V. Oliveira and A. Costa, “Cerebral Hematoma Caused by Mucormycosis,” Revista de Neurología, Vol. 33, No. 10, 2001, pp. 951-953.
|
|
[5]
|
D. S. Marques, C. Pinho Vaz, R. Branca, et al., “Rhizomucor and Scedosporium Infection Post Hematopoietic Stem-Cell Transplant,” Case Reports in Medicine, Vol. 2011, 2011, Article ID: 830769.
|
|
[6]
|
M. M. Roden, T. E. Zaoutis, W. L. Buchanan, et al., “Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases,” Clinical Infectious Diseases, Vol. 41, No. 5, 2005, pp. 634-653.
http://dx.doi.org/10.1086/432579
|
|
[7]
|
B. Rammaert, F. Lanternier, S. Poiree, R. Kania and O. Lortholary, “Diabetes and Mucormycosis: A Complex Interplay,” Diabetes & Metabolism, Vol. 38, No. 3, 2012, pp. 193-204.
http://dx.doi.org/10.1016/j.diabet.2012.01.002
|
|
[8]
|
U. Wali, A. Balkhair and A. Al-Mujaini, “Cerebro-Rhino Orbital Mucormycosis: An Update,” The Journal of Infection and Public Health, Vol. 5, No. 2, 2012, pp. 116126.
http://dx.doi.org/10.1016/j.jiph.2012.01.003
|
|
[9]
|
S. M. Trifilio, C. L. Bennett, P. R. Yarnold, et al., “Breakthrough Zygomycosis after Voriconazole Administration among Patients with Hematologic Malignancies Who Receive Hematopoietic Stem-Cell Transplants or Intensive Chemotherapy,” Bone Marrow Transplant, Vol. 39, No. 7, 2007, pp. 425-429.
http://dx.doi.org/10.1038/sj.bmt.1705614
|
|
[10]
|
D. P. Kontoyiannis, M. S. Lionakis, R. E. Lewis, et al., “Zygomycosis in a Tertiary-Care Cancer Center in the Era of Aspergillus-Active Antifungal Therapy: A CaseControl Observational Study of 27 Recent Cases,” The Journal of Infectious Diseases, Vol. 191, No. 8, 2005, pp. 1350-1360.
http://dx.doi.org/10.1086/428780
|
|
[11]
|
L. Pagano, B. Gleissner, L. Fianchi, “Breakthrough Zygomycosis and Voriconazole,” The Journal of Infectious Diseases, Vol. 192, No. 8, 2005, pp. 1496-1497.
http://dx.doi.org/10.1086/444433
|
|
[12]
|
L. Luo and T. Li, “Idiopathic CD4 Lymphocytopenia and Opportunistic Infection—An Update,” FEMS Immunology and Medical Microbiology, Vol. 54, No. 3, 2008, pp. 283-289.
http://dx.doi.org/10.1111/j.1574-695X.2008.00490.x
|
|
[13]
|
S. Antinori, M. Nebuloni, C. Magni, et al., “Trends in the Postmortem Diagnosis of Opportunistic Invasive Fungal Infections in Patients with AIDS: A Retrospective Study of 1630 Autopsies Performed between 1984 and 2002,” American Journal of Clinical Pathology, Vol. 132, No. 2, 2009, pp. 221-227.
http://dx.doi.org/10.1309/AJCPRAAE8LZ7DTNE
|
|
[14]
|
L. Nichols, R. Z. Ocque and I. Daly, “Zygomycosis Associated with HIV Infection and Liver Transplantation,” Pathology Research International, Vol. 2011, 2011, Article ID: 545981.
|
|
[15]
|
H. Y. Sun and N. Singh, “Mucormycosis: Its Contemporary Face and Management Strategies,” The Lancet Infectious Diseases, Vol. 11, No. 4, 2011, pp. 301-311.
http://dx.doi.org/10.1016/S1473-3099(10)70316-9
|
|
[16]
|
T. J. Walsh, M. N. Gamaletsou, M. R. McGinnis, R. T. Hayden and D. P. Kontoyiannis, “Early Clinical and Laboratory Diagnosis of Invasive Pulmonary, Extrapulmonary, and Disseminated Mucormycosis (Zygomycosis),” Clinical Infectious Diseases, Vol. 54, No. S1, 2012, pp. S55-S60.
http://dx.doi.org/10.1093/cid/cir868
|
|
[17]
|
B. Spellberg, A. Ibrahim, E. Roilides, et al., “Combination Therapy for Mucormycosis: Why, What, and How?” Clinical Infectious Diseases, Vol. 54, No. S1, 2012, pp. S73-S78.
http://dx.doi.org/10.1093/cid/cir885
|
|
[18]
|
C. Reed, R. Bryant, A. S. Ibrahim, et al., “Combination Polyene-Caspofungin Treatment of Rhino-Orbital-Cerebral Mucormycosis,” Clinical Infectious Diseases, Vol. 47, No. 3, 2008, pp. 364-371.
http://dx.doi.org/10.1086/589857
|
|
[19]
|
A. Tragiannidis and A. H. Groll, “Hyperbaric Oxygen Therapy and Other Adjunctive Treatments for Zygomycosis,” Clinical Microbiology and Infection, Vol. 15, No. S5, 2009, pp. 82-86.
http://dx.doi.org/10.1111/j.1469-0691.2009.02986.x
|
|
[20]
|
A. Safdar, “Immunotherapy for Invasive Mold Disease in Severely Immunosuppressed Patients,” Clinical Infectious Diseases, Vol. 57, No. 1, 2013, pp. 94-100.
http://dx.doi.org/10.1093/cid/cit187
|